Analysis and Commentary STEVEN GROSSMAN 12/15/17 Analysis and Commentary STEVEN GROSSMAN 12/15/17 Right Down to the Wire: Beware and Be Warned! Read More Advocacy at a Glance STEVEN GROSSMAN 12/15/17 Advocacy at a Glance STEVEN GROSSMAN 12/15/17 CR Expires December 22; No Clear Path to Completion and more Read More Analysis and Commentary STEVEN GROSSMAN 12/8/17 Analysis and Commentary STEVEN GROSSMAN 12/8/17 "All of Our Voices" Are Going to Be Essential Read More Advocacy at a Glance STEVEN GROSSMAN 12/8/17 Advocacy at a Glance STEVEN GROSSMAN 12/8/17 Suspended Debt Ceiling Back in Play and more Read More Analysis and Commentary STEVEN GROSSMAN 12/1/17 Analysis and Commentary STEVEN GROSSMAN 12/1/17 No One’s Interests Would Be Served by a Shutdown Read More Advocacy at a Glance STEVEN GROSSMAN 12/1/17 Advocacy at a Glance STEVEN GROSSMAN 12/1/17 CR Runs Out on December 8: Will There Be a Budget Deal or a Shutdown and more Read More Analysis and Commentary STEVEN GROSSMAN 11/17/17 Analysis and Commentary STEVEN GROSSMAN 11/17/17 Much to Be Thankful For Read More Advocacy at a Glance STEVEN GROSSMAN 11/17/17 Advocacy at a Glance STEVEN GROSSMAN 11/17/17 FDA and Thanksgiving: They Go Together and more Read More Analysis and Commentary STEVEN GROSSMAN 11/10/17 Analysis and Commentary STEVEN GROSSMAN 11/10/17 Whatever Makes FDA Stronger (in Resources) ... Read More Advocacy at a Glance STEVEN GROSSMAN 11/10/17 Advocacy at a Glance STEVEN GROSSMAN 11/10/17 Why Does the Alliance Advocate for Funding All of FDA and more Read More Analysis and Commentary STEVEN GROSSMAN 11/4/17 Analysis and Commentary STEVEN GROSSMAN 11/4/17 FDA Is Its People ... and They Need Our Support Read More Advocacy at a Glance STEVEN GROSSMAN 11/4/17 Advocacy at a Glance STEVEN GROSSMAN 11/4/17 Worth A Second Look: “Not Your Father’s FDA” and more Read More Analysis and Commentary STEVEN GROSSMAN 10/27/17 Analysis and Commentary STEVEN GROSSMAN 10/27/17 Building a Truely 21st Century Regulatory Agency Read More Advocacy at a Glance STEVEN GROSSMAN 10/27/17 Advocacy at a Glance STEVEN GROSSMAN 10/27/17 FDA Wants Public Input on Improving the Agency’s Website Read More Analysis and Commentary STEVEN GROSSMAN 10/20/17 Analysis and Commentary STEVEN GROSSMAN 10/20/17 Not Your Father's FDA Read More Advocacy at a Glance STEVEN GROSSMAN 10/20/17 Advocacy at a Glance STEVEN GROSSMAN 10/20/17 Changes and Growth at the FDA Read More Analysis and Commentary STEVEN GROSSMAN 10/13/17 Analysis and Commentary STEVEN GROSSMAN 10/13/17 The FDA Deserves Special Consideration at Budget-Time Read More Advocacy at a Glance STEVEN GROSSMAN 10/13/17 Advocacy at a Glance STEVEN GROSSMAN 10/13/17 Senate Budget Vote Likely the Week of October 16 Read More Analysis and Commentary STEVEN GROSSMAN 10/6/17 Analysis and Commentary STEVEN GROSSMAN 10/6/17 FDA Stakeholders Need to Start to "Up Our Game" Read More Advocacy at a Glance STEVEN GROSSMAN 10/6/17 Advocacy at a Glance STEVEN GROSSMAN 10/6/17 House Passes FY 18 Budget Resolution; Differs from Senate Version and more Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 12/15/17 Analysis and Commentary STEVEN GROSSMAN 12/15/17 Right Down to the Wire: Beware and Be Warned! Read More
Advocacy at a Glance STEVEN GROSSMAN 12/15/17 Advocacy at a Glance STEVEN GROSSMAN 12/15/17 CR Expires December 22; No Clear Path to Completion and more Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/17 Analysis and Commentary STEVEN GROSSMAN 12/8/17 "All of Our Voices" Are Going to Be Essential Read More
Advocacy at a Glance STEVEN GROSSMAN 12/8/17 Advocacy at a Glance STEVEN GROSSMAN 12/8/17 Suspended Debt Ceiling Back in Play and more Read More
Analysis and Commentary STEVEN GROSSMAN 12/1/17 Analysis and Commentary STEVEN GROSSMAN 12/1/17 No One’s Interests Would Be Served by a Shutdown Read More
Advocacy at a Glance STEVEN GROSSMAN 12/1/17 Advocacy at a Glance STEVEN GROSSMAN 12/1/17 CR Runs Out on December 8: Will There Be a Budget Deal or a Shutdown and more Read More
Analysis and Commentary STEVEN GROSSMAN 11/17/17 Analysis and Commentary STEVEN GROSSMAN 11/17/17 Much to Be Thankful For Read More
Advocacy at a Glance STEVEN GROSSMAN 11/17/17 Advocacy at a Glance STEVEN GROSSMAN 11/17/17 FDA and Thanksgiving: They Go Together and more Read More
Analysis and Commentary STEVEN GROSSMAN 11/10/17 Analysis and Commentary STEVEN GROSSMAN 11/10/17 Whatever Makes FDA Stronger (in Resources) ... Read More
Advocacy at a Glance STEVEN GROSSMAN 11/10/17 Advocacy at a Glance STEVEN GROSSMAN 11/10/17 Why Does the Alliance Advocate for Funding All of FDA and more Read More
Analysis and Commentary STEVEN GROSSMAN 11/4/17 Analysis and Commentary STEVEN GROSSMAN 11/4/17 FDA Is Its People ... and They Need Our Support Read More
Advocacy at a Glance STEVEN GROSSMAN 11/4/17 Advocacy at a Glance STEVEN GROSSMAN 11/4/17 Worth A Second Look: “Not Your Father’s FDA” and more Read More
Analysis and Commentary STEVEN GROSSMAN 10/27/17 Analysis and Commentary STEVEN GROSSMAN 10/27/17 Building a Truely 21st Century Regulatory Agency Read More
Advocacy at a Glance STEVEN GROSSMAN 10/27/17 Advocacy at a Glance STEVEN GROSSMAN 10/27/17 FDA Wants Public Input on Improving the Agency’s Website Read More
Analysis and Commentary STEVEN GROSSMAN 10/20/17 Analysis and Commentary STEVEN GROSSMAN 10/20/17 Not Your Father's FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 10/20/17 Advocacy at a Glance STEVEN GROSSMAN 10/20/17 Changes and Growth at the FDA Read More
Analysis and Commentary STEVEN GROSSMAN 10/13/17 Analysis and Commentary STEVEN GROSSMAN 10/13/17 The FDA Deserves Special Consideration at Budget-Time Read More
Advocacy at a Glance STEVEN GROSSMAN 10/13/17 Advocacy at a Glance STEVEN GROSSMAN 10/13/17 Senate Budget Vote Likely the Week of October 16 Read More
Analysis and Commentary STEVEN GROSSMAN 10/6/17 Analysis and Commentary STEVEN GROSSMAN 10/6/17 FDA Stakeholders Need to Start to "Up Our Game" Read More
Advocacy at a Glance STEVEN GROSSMAN 10/6/17 Advocacy at a Glance STEVEN GROSSMAN 10/6/17 House Passes FY 18 Budget Resolution; Differs from Senate Version and more Read More
